ELIAS Animal Health Blog
Read the latest news and updates from ELIAS Animal Health
USDA Agrees Clinical Trial Data for the ELIAS Cancer Immunotherapy (ECI®) Demonstrates Reasonable Expectation of Efficacy for the Treatment of Bone Cancer in Dogs
First-in-class adoptive cell therapy for treatment of osteosarcoma, a deadly form of bone cancer in dogs OLATHE, Kan., Jan. 17, [...]
New Clinical Trial Will Evaluate Combination Therapy to Treat Canine Lymphoma
After successfully concluding a clinical trial for canine osteosarcoma, ELIAS Animal Health is focused on continuing to push forward in [...]
ELIAS Animal Health Research Demonstrates Cancer-Killing Capabilities of Its Activated T Cell Immunotherapy
In vitro study of the ELIAS Cancer Immunotherapy (ECI®) showed personalized T cell immunotherapy initiated a significant immune response [...]
ELIAS Animal Health Expands Scientific Advisory Board
Nov. 23, 2021 — ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, [...]
ELIAS Animal Health In-Licenses Oncolytic Vaccinia Virus Treatment for Pet Animals from Genelux Corporation
Agreement grants ELIAS Animal Health the worldwide right to development and commercialization of V-VET1 for the diagnosis, prevention and treatment [...]
ELIAS Animal Health Launches Clinical Trial Of Cancer Immunotherapy Treatment For Canine Oral Melanoma
Olathe, Kan., August 31, 2021 – ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion [...]
Long-term bone cancer survivor and ECI® patient featured on local news
Ruby the Greyhound was diagnosed with osteosarcoma in December 2016 and began the ELIAS cancer immunotherapy (ECI®). Today, Ruby [...]